Ongentys (Opicapone), as a third-generation COMT inhibitor, is mainly used as an adjuvant therapy for Parkinson's disease patients, improving motor fluctuation symptoms by prolonging the action time of levodopa.

1 Core therapeutic function

(1) Indication positioning: As an adjuvant medication for levodopa/carbidopa, specifically targeting the "off phase" symptoms that occur during the treatment of Parkinson's disease.

(2) Mechanism of action: By reversibly inhibiting peripheral COMT enzyme, the metabolism of levodopa is reduced by 60%, significantly prolonging its plasma half-life.

2 Clinical efficacy manifestations

(1) Symptom improvement: Daily single dose administration can prolong the "on period" time by 1.5-2 hours and reduce the frequency of "off period" attacks by 30-40%.

(2) Advantages of medication: Compared to traditional COMT inhibitors, it has a more potent and long-lasting peripheral COMT inhibitory effect.

3 Special therapeutic values

(1) Convenience of administration: The 50mg bedtime single dose regimen significantly improves medication adherence.

(2) Less drug interactions: Not metabolized by CYP450 enzymes, reducing the risk of interactions with other drugs.